RINVOQ

Prolonged-release tablet, 30mg
RxActive license

Active substance (INN)

upadacitinib

Pharmaceutical form

Pharmaceutical formProlonged-release tablet
Strength30mg
PackagingUkupno 28 tableta sa produženim oslobađanjem u blisteru (4x7) u kartonskoj kutiji
ManufacturerAbbVie Logistics B.V., Netherlands
Therapeutic groupAntineoplastic and immunomodulating agents (L04AF03)
Marketing authorization holderDRUŠTVO ZA TRGOVINU NA VELIKO FARMACEUTSKIM PROIZVODIMA "GLOSARIJ" D.O.O.-PODGORICA
Authorization dateAugust 28, 2024

Analogs in Montenegro

2

Other medicines with the same active substance

RINVOQRx
Prolonged-release tablet, 15mgAbbVie Logistics B.V.
RINVOQRx
Prolonged-release tablet, 45mgAbbVie Logistics B.V.
Source: CInMED register